Company Overview
CRISPR Therapeutics AG is a specialized gene editing company dedicated to developing gene-based medicines designed to treat serious human diseases. The organization utilizes its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform, which serves as a sophisticated technology for gene editing. Operating within the Healthcare sector and the Biotechnology industry, the company leverages advanced scientific methodologies to address significant medical challenges. The firm currently holds a market capitalization of $4.51B, while its annual revenue for the trailing twelve months stands at $3.51M with an undisclosed employee count. The substantial market cap of $4.51B relative to the modest revenue of $3.51M indicates that the company's valuation is driven primarily by future potential and intellectual property rather than current cash flow generation. This disparity highlights a typical profile for biotechnology firms in the development phase, where investor capital supports high-risk research and development activities before commercial products generate substantial income.
Financial Health
The company reported a revenue of $3.51M for the trailing twelve months, yet it recorded a net income of $-581,598,976 and an EBITDA of $-548,838,976. The massive gap between the minimal revenue and the substantial net loss reveals a cost structure dominated by heavy research and development expenditures rather than operational efficiencies. Furthermore, the free cash flow stands at $-205,623,744, which signifies that the company is burning cash to fund its operations and development pipeline. Despite these outflows, the balance sheet contains $1.98B in cash, which provides a significant buffer against the $206.75M in debt. The debt-to-equity ratio is listed at 10.76, suggesting a leveraged position where debt obligations are substantial relative to equity, yet the available cash liquidity suggests the company is not in immediate distress. The current ratio is 13.32, indicating an extremely high level of short-term liquidity and the ability to cover liabilities well in excess of current obligations. However, the gross margin is 0.0%, the operating margin is -17912.5%, and the profit margin is 0.0%, reflecting that the company is not yet profitable on a per-unit or per-revenue basis. Return on Equity is -30.2% and Return on Assets is -15.8%, metrics that indicate management is currently generating negative returns on the capital invested in the company. These negative return metrics are characteristic of early-stage biotechnology firms that are prioritizing asset growth and clinical trial progress over immediate profitability.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is -11.17, implying that the market prices the stock based on anticipated future earnings rather than current performance. The price-to-book ratio is 2.34, which indicates that the market values the company at a premium of roughly 2.3 times its book value. The price-to-sales ratio is 1283.91, a metric that suggests investors are willing to pay a very high multiple for each dollar of sales, driven by expectations of future blockbuster therapies. Additionally, the EV/EBITDA stands at -4.99, further confirming that traditional earnings-based valuation models are not applicable in the current stage of the business lifecycle. The stock has a 52-week high of $78.48 and a 52-week low of $30.04, creating a trading range of $48.44. Without a specific current price provided in the source data, the position relative to this range cannot be calculated precisely, but the wide range illustrates significant price volatility inherent in the biotechnology sector. The beta value is 1.74, meaning the stock's price volatility is expected to be 74% higher than the broader market. This high beta indicates that the asset is significantly more sensitive to market movements and macroeconomic shifts than large-cap healthcare stocks.
Growth & Income
The revenue growth year-over-year is -97.6%, while earnings growth year-over-year is N/A, reflecting the absence of consistent profitability to measure against prior periods. The lack of positive earnings growth relative to the declining revenue indicates that the company is not yet in a commercial scaling phase where sales growth drives profit expansion. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute profits to shareholders but instead retains all earnings. This reinvestment strategy is typical for growth-oriented biotechnology firms that require capital to fund clinical trials and regulatory approvals rather than rewarding shareholders with income. The overall growth and income profile is defined by a high-risk, high-potential trajectory where current financial metrics reflect negative growth and zero income distribution. The company's financial structure supports a long-term value creation model that relies on the successful commercialization of its gene editing platform rather than short-term financial performance.